307 related articles for article (PubMed ID: 11526490)
1. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.
Tuveson DA; Willis NA; Jacks T; Griffin JD; Singer S; Fletcher CD; Fletcher JA; Demetri GD
Oncogene; 2001 Aug; 20(36):5054-8. PubMed ID: 11526490
[TBL] [Abstract][Full Text] [Related]
2. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
[TBL] [Abstract][Full Text] [Related]
3. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs).
Duensing A; Medeiros F; McConarty B; Joseph NE; Panigrahy D; Singer S; Fletcher CD; Demetri GD; Fletcher JA
Oncogene; 2004 May; 23(22):3999-4006. PubMed ID: 15007386
[TBL] [Abstract][Full Text] [Related]
5. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
Attoub S; Rivat C; Rodrigues S; Van Bocxlaer S; Bedin M; Bruyneel E; Louvet C; Kornprobst M; André T; Mareel M; Mester J; Gespach C
Cancer Res; 2002 Sep; 62(17):4879-83. PubMed ID: 12208734
[TBL] [Abstract][Full Text] [Related]
6. Analysis of signal transducer and activator of transcription 3 (STAT3) in gastrointestinal stromal tumors.
Paner GP; Silberman S; Hartman G; Micetich KC; Aranha GV; Alkan S
Anticancer Res; 2003; 23(3B):2253-60. PubMed ID: 12894500
[TBL] [Abstract][Full Text] [Related]
7. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST).
Ali S; Ali S
Gene; 2007 Oct; 401(1-2):38-45. PubMed ID: 17659849
[TBL] [Abstract][Full Text] [Related]
8. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling.
Tarn C; Merkel E; Canutescu AA; Shen W; Skorobogatko Y; Heslin MJ; Eisenberg B; Birbe R; Patchefsky A; Dunbrack R; Arnoletti JP; von Mehren M; Godwin AK
Clin Cancer Res; 2005 May; 11(10):3668-77. PubMed ID: 15897563
[TBL] [Abstract][Full Text] [Related]
9. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
Bauer S; Duensing A; Demetri GD; Fletcher JA
Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049
[TBL] [Abstract][Full Text] [Related]
10. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.
Chen LL; Trent JC; Wu EF; Fuller GN; Ramdas L; Zhang W; Raymond AK; Prieto VG; Oyedeji CO; Hunt KK; Pollock RE; Feig BW; Hayes KJ; Choi H; Macapinlac HA; Hittelman W; Velasco MA; Patel S; Burgess MA; Benjamin RS; Frazier ML
Cancer Res; 2004 Sep; 64(17):5913-9. PubMed ID: 15342366
[TBL] [Abstract][Full Text] [Related]
11. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
[TBL] [Abstract][Full Text] [Related]
12. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.
Bauer S; Corless CL; Heinrich MC; Dirsch O; Antoch G; Kanja J; Seeber S; Schütte J
Cancer Chemother Pharmacol; 2003 Mar; 51(3):261-5. PubMed ID: 12655446
[TBL] [Abstract][Full Text] [Related]
13. Pathology of gastrointestinal stromal tumors.
Hirota S; Isozaki K
Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
[TBL] [Abstract][Full Text] [Related]
14. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
[TBL] [Abstract][Full Text] [Related]
15. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.
Zermati Y; De Sepulveda P; Féger F; Létard S; Kersual J; Castéran N; Gorochov G; Dy M; Ribadeau Dumas A; Dorgham K; Parizot C; Bieche Y; Vidaud M; Lortholary O; Arock M; Hermine O; Dubreuil P
Oncogene; 2003 Feb; 22(5):660-4. PubMed ID: 12569358
[TBL] [Abstract][Full Text] [Related]
16. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR
Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics.
Miettinen M; Lasota J
Pol J Pathol; 2003; 54(1):3-24. PubMed ID: 12817876
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias.
Blay P; Astudillo A; Buesa JM; Campo E; Abad M; García-García J; Miquel R; Marco V; Sierra M; Losa R; Lacave A; Braña A; Balbín M; Freije JM
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4089-95. PubMed ID: 15217944
[TBL] [Abstract][Full Text] [Related]
19. STI571 inhibits growth and adhesion of human mast cells in culture.
Takeuchi K; Koike K; Kamijo T; Ishida S; Nakazawa Y; Kurokawa Y; Sakashita K; Kinoshita T; Matsuzawa S; Shiohara M; Yamashita T; Nakajima M; Komiyama A
J Leukoc Biol; 2003 Dec; 74(6):1026-34. PubMed ID: 12960256
[TBL] [Abstract][Full Text] [Related]
20. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.
Bauer S; Yu LK; Demetri GD; Fletcher JA
Cancer Res; 2006 Sep; 66(18):9153-61. PubMed ID: 16982758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
